AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16960168 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage with carbohydrate-containing meal
Number of subjects: 0
Study 16960168 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage with lipid-containing meal
Number of subjects: 0
Study 12848875 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (GP)
Number of subjects: 40
Study 12848875 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment of AMI-I (GCT)
Number of subjects: 40
Study 12848875 — intervention group
Group type: COMPARATOR
Intervention: Control group (COG)
Number of subjects: 40
Study 10783989 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (high-dose radiation)
Number of subjects: 0
Study 10783989 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (combination of chemotherapy and radiation)
Number of subjects: 0
Study 10783989 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modality therapy (combination of treatments)
Number of subjects: 0
Study 8796164 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 2% prilocaine
Number of subjects: 50
Study 8796164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anaesthesia with 2% prilocaine
Number of subjects: 50
Study 1537492 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23
Study 1537492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6233148 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (administered intravenously)
Number of subjects: 6
Study 27062245 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute motivational interviewing-based session delivered by a therapist plus educational enhanced usual care (EUC)
Number of subjects: 204
Study 27062245 — intervention group
Group type: COMPARATOR
Intervention: Educational enhanced usual care (EUC) alone
Number of subjects: 204
Study 24898089 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention (manual‐based coping strategy programme)
Number of subjects: 75
Study 24898089 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 75
Study 22180633 — intervention group
Group type: COMPARATOR
Intervention: ANA 150 mg/day
Number of subjects: 30
Study 22180633 — intervention group
Group type: COMPARATOR
Intervention: ANA 20 mg/day
Number of subjects: 30
Study 19906799 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonally adjusted 25(OH)D concentration <50 nmol/L
Number of subjects: 1471
Study 16698176 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine 15 mg t.i.d.
Number of subjects: 131
Study 16698176 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 5 mg t.i.d.
Number of subjects: 131
Study 16129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (mean dose 448 mg)
Number of subjects: 94
Study 16129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (mean dose 55 mg)
Number of subjects: 94
Study 16129989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 16129989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol and Amitriptyline
Number of subjects: 94
Study 12006895 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg for the first 8 weeks, then increased by 20 mg every two weeks to a maximum of 60 mg/day)
Number of subjects: 60
Study 12006895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10051933 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms.kg‐1 po given 60‐90 min preoperatively
Number of subjects: 36
Study 10051933 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 3 micrograms.kg‐1 i.v. given intraoperatively
Number of subjects: 36
Study 7977446 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalamin serum assay
Number of subjects: 1599
Study 2732068 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-session CVD risk reduction intervention
Number of subjects: 1447
Study 53376 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (T.F.) prepared from patients with Hodgkin's disease in long remission
Number of subjects: 6
Study 53376 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (T.F.)
Number of subjects: 6
Study 31369706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovaza (n‐3FA)
Number of subjects: 20
Study 28066708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 17
Study 28066708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 25700621 — intervention group
Group type: EXPERIMENTAL
Intervention: DY-807f (360 mg)
Number of subjects: 84
Study 25700621 — intervention group
Group type: COMPARATOR
Intervention: DY-807f (60 mg)
Number of subjects: 84
Study 25700621 — intervention group
Group type: EXPERIMENTAL
Intervention: DY-807f (various doses: 10, 30, 60, 120, 240, 360 mg)
Number of subjects: 84
Study 25700621 — intervention group
Group type: EXPERIMENTAL
Intervention: DY-807f
Number of subjects: 84
Study 24423149 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg saxagliptin for 6 weeks
Number of subjects: 50
Study 24423149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23071824 — intervention group
Group type: EXPERIMENTAL
Intervention: Real continuous theta burst stimulation (cTBS)
Number of subjects: 0
Study 23071824 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous theta burst stimulation (cTBS)
Number of subjects: 0
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural sectors including horticulture/fruit growing
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant nurseries
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable growing
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Market farmers/crop growers
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Field crop/vegetable growers
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Market gardeners
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursery growers/workers
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber/plastics products machine operators
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailors and dressmakers
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaners
Number of subjects: 696
Study 18953052 — intervention group
Group type: EXPERIMENTAL
Intervention: Builder's labourers
Number of subjects: 696
Study 17518968 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits for advising mothers about breastfeeding and weaning; Duration: 10 days after birth, monthly up to 6 months, at 8, 10, and 12 months; Based on 'Ten Steps for Healthy Feeding'
Number of subjects: 500
Study 17518968 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 500
Study 15601310 — intervention group
Group type: EXPERIMENTAL
Intervention: Troxerutin (50 mg) and Zn gluconate (25 mg)
Number of subjects: 94
Study 15601310 — intervention group
Group type: COMPARATOR
Intervention: Control treatment with 10 mg Zn gluconate
Number of subjects: 94
Study 12489528 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Play preparation
Number of subjects: 42
Study 12489528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Therapeutic Play preparation)
Number of subjects: 42
Study 9774209 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.8 g/100 ml commercial carbohydrate‐electrolyte (CHO) beverage (39 +/‐ 4 g of CHO)
Number of subjects: 14
Study 9774209 — intervention group
Group type: COMPARATOR
Intervention: Coloured, flavoured placebo
Number of subjects: 14
Study 8151323 — intervention group
Group type: COMPARATOR
Intervention: DTIC 800 mg/m2 IV days 1 and 21
Number of subjects: 266
Study 8151323 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus rIFN alpha 2a 9 mIU IM daily
Number of subjects: 266
Study 8151323 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus rIFN alpha 2a 3 mIU IM three times per week
Number of subjects: 266
Study 2894106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms kg‐1
Number of subjects: 100
Study 2894106 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms kg‐1
Number of subjects: 100
Study 2894106 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alfentanil)
Number of subjects: 100
Study 2254503 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention incorporating parent coaching, attentional distraction, and positive reinforcement
Number of subjects: 23
Study 2254503 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 23
Study 175696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pions
Number of subjects: 0
Study 175696 — intervention group
Group type: COMPARATOR
Intervention: X rays
Number of subjects: 0
Study 31206995 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with no label
Number of subjects: 87
Study 31206995 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition with a novel label
Number of subjects: 87
Study 31206995 — intervention group
Group type: COMPARATOR
Intervention: Baseline control condition
Number of subjects: 87
Study 31796472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic venous pressure gradient (HVPG) calculated using biofluid mechanics model in original cohort
Number of subjects: 248
Study 31796472 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of HVPG using biofluid mechanics model in validation cohort
Number of subjects: 248
Study 28641737 — intervention group
Group type: EXPERIMENTAL
Intervention: Home- and class-based exercise program
Number of subjects: 12
Study 25038508 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary instrumentation
Number of subjects: 80
Study 25038508 — intervention group
Group type: COMPARATOR
Intervention: Manual instrumentation (Control)
Number of subjects: 80
Study 24108515 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids (gelatins, dextrans, hydroxyethyl starches, or 4% or 20% of albumin)
Number of subjects: 2857
Study 24108515 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids (isotonic or hypertonic saline or Ringer lactate solution)
Number of subjects: 2857
Study 24108515 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloids
Number of subjects: 2857
Study 24108515 — intervention group
Group type: COMPARATOR
Intervention: Crystalloids
Number of subjects: 2857
Study 21497330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual end-state comfort task with 11 letters for memory recall
Number of subjects: 72
Study 21497330 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual task moving non-descript plastic cylinder(s)
Number of subjects: 72
Study 21497330 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimanual task moving non-descript plastic cylinder(s)
Number of subjects: 72
Study 19630069 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Training (ERT) plus treatment as usual (TAU)
Number of subjects: 43
Study 19630069 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 43
Study 17714618 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg of misoprostol
Number of subjects: 64
Study 17714618 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B6 placebo
Number of subjects: 64
Study 15385907 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session peer mentoring intervention
Number of subjects: 1161
Study 15385907 — intervention group
Group type: COMPARATOR
Intervention: 8-session videotape control
Number of subjects: 1161
Study 11798216 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the WHO analgesic ladder, appropriate opioid dose escalation, use of adjuvant analgesics, and non-pharmacological methods of pain control
Number of subjects: 0
Study 10098460 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 activity
Number of subjects: 0
Study 10098460 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot morning urine samples
Number of subjects: 0
Study 7819722 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography
Number of subjects: 65
Study 7819722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium 201 SPECT
Number of subjects: 65
Study 7819722 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography and 201Tl SPECT combined
Number of subjects: 65
Study 3260467 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 or Lentinan in PCM mice
Number of subjects: 0
Study 3260467 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 and OK-432 in C 3H/He mice
Number of subjects: 0
Study 3260467 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC and FT(MF) with Lentinan
Number of subjects: 0
Study 3260467 — intervention group
Group type: COMPARATOR
Intervention: MMC and FT(MF) without Lentinan
Number of subjects: 0
Study 31629060 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (500 μg every 3 weeks)
Number of subjects: 2516
Study 31629060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2516
Study 30257178 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for illicit drug use linked to ASSIST
Number of subjects: 82
Study 27521809 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-Release Naltrexone (XR-NTX)
Number of subjects: 600
Study 27521809 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (BUP-NX)
Number of subjects: 600
Study 24691923 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised HIV self-testing (HST)
Number of subjects: 246
Study 24691923 — intervention group
Group type: COMPARATOR
Intervention: Provider-supervised HIV self-testing (HST)
Number of subjects: 246
Study 22967728 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic phenomena
Number of subjects: 117
Study 22967728 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological phenomena
Number of subjects: 117
Study 22967728 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial framework
Number of subjects: 117
Study 22967728 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological construct of 'tension' or 'worry'
Number of subjects: 117
Study 22967728 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 117
Study 20215608 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Number of subjects: 947
Study 20215608 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 947
Study 20215608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study participants (both vaccinated and non-vaccinated)
Number of subjects: 947
Study 17824897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) with output current ranging from 0.25 to 1.5 mA
Number of subjects: 61
Study 17824897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) with increased output current
Number of subjects: 61
Study 17824897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) with low current (<1 mA)
Number of subjects: 61
Study 16143732 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 127
Study 16143732 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered supportive emotion-focused therapy (Control)
Number of subjects: 127
Study 11812697 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine 2% (CP)
Number of subjects: 22
Study 11812697 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine 2% and sodium bicarbonate 8.4% (CP+BIC)
Number of subjects: 22
Study 11812697 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 1% (L)
Number of subjects: 22
Study 11812697 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 1% and sodium bicarbonate 8.4% (L+BIC)
Number of subjects: 22
Study 11812697 — intervention group
Group type: COMPARATOR
Intervention: normal saline solution 0.9% (NSS)
Number of subjects: 22
Study 11812697 — intervention group
Group type: COMPARATOR
Intervention: sodium bicarbonate 8.4% (BIC)
Number of subjects: 22
Study 10583337 — intervention group
Group type: EXPERIMENTAL
Intervention: H-wave therapy at 2 Hz
Number of subjects: 36
Study 10583337 — intervention group
Group type: EXPERIMENTAL
Intervention: H-wave therapy at 60 Hz
Number of subjects: 36
Study 10583337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8722349 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF + Epo (150 U/kg, from day +1 to +21)
Number of subjects: 30
Study 8722349 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 micrograms/kg, from day +1 up to reaching an ANC > or = 10(9)/1)
Number of subjects: 30
Study 8722349 — intervention group
Group type: COMPARATOR
Intervention: Control (neither G-CSF nor Epo)
Number of subjects: 30
Study 2060514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 320
Study 2060514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 320
Study 2060514 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 320
Study 2060514 — intervention group
Group type: COMPARATOR
Intervention: All agents (Cefoperazone, Ceftizoxime, Ceftriaxone)
Number of subjects: 320
Study 2060514 — intervention group
Group type: COMPARATOR
Intervention: All infections
Number of subjects: 320
Study 2060514 — intervention group
Group type: COMPARATOR
Intervention: Pneumonia
Number of subjects: 320
Study 2060514 — intervention group
Group type: COMPARATOR
Intervention: Gram-negative infections
Number of subjects: 320
Study 2060514 — intervention group
Group type: COMPARATOR
Intervention: Gram-positive infections
Number of subjects: 320
Study 2060514 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (once daily vs twice daily)
Number of subjects: 320
Study 2060514 — intervention group
Group type: COMPARATOR
Intervention: All three agents
Number of subjects: 320
Study 6337428 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) plus Persantine (75 mg) four times daily
Number of subjects: 750
Study 6337428 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (325 mg) plus placebo four times daily
Number of subjects: 750
Study 28853051 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (16-week program)
Number of subjects: 206
Study 28853051 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 206
Study 27393722 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-time dosing of basal insulin peglispro (BIL)
Number of subjects: 212
Study 27393722 — intervention group
Group type: COMPARATOR
Intervention: Fixed-time dosing of basal insulin peglispro (BIL)
Number of subjects: 212
Study 23184419 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium binoxalate gel (group A, 40 teeth)
Number of subjects: 20
Study 23184419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (group B, 40 teeth: 1 W, 10 Hz, 60 s, irradiated twice)
Number of subjects: 20
Study 22928390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dwell time of 60 seconds (G3)
Number of subjects: 15
Study 22928390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dwell time of 30 seconds (G2)
Number of subjects: 15
Study 22928390 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1, no extra dwell time)
Number of subjects: 15
Study 22928390 — intervention group
Group type: EXPERIMENTAL
Intervention: Dwell time of 30 seconds (G2) and 60 seconds (G3)
Number of subjects: 15
Study 20302662 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular therapeutic protocol with radio electric stimulator device (REAC)
Number of subjects: 200
Study 20302662 — intervention group
Group type: COMPARATOR
Intervention: Inactivated, placebo REAC
Number of subjects: 200
Study 17268158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose milrinone (25 microg/kg loading dose, followed by 0.25 microg/kg/min maintenance)
Number of subjects: 47
Study 17268158 — intervention group
Group type: COMPARATOR
Intervention: Control group (no milrinone)
Number of subjects: 47
Study 17268158 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose milrinone
Number of subjects: 47
Study 15608541 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 439
Study 15608541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 439
Study 15608541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and cognitive-behavioral therapy
Number of subjects: 439
Study 15608541 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 439
Study 12215960 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 32
Study 12215960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and mental training
Number of subjects: 32
Study 12215960 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental training
Number of subjects: 32
Study 12215960 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 10195971 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety advice at child health surveillance consultations, provision of low cost safety equipment, home safety checks, and first aid training.
Number of subjects: 0
Study 7772425 — intervention group
Group type: EXPERIMENTAL
Intervention: No cricoid pressure applied
Number of subjects: 22
Study 7772425 — intervention group
Group type: COMPARATOR
Intervention: Cricoid pressure applied (30 N)
Number of subjects: 22
Study 2178426 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 4013
Study 2178426 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 4013
Study 7241441 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone administered in increments based on body weight and time, with suxamethonium for relaxation.
Number of subjects: 75
Study 7241441 — intervention group
Group type: EXPERIMENTAL
Intervention: Small aliquots of lignocaine for reducing injection pain, given before or mixed with methohexitone.
Number of subjects: 75